Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Omega 3: Cardiovascular disease - Nutraceuticals World

What are you searching for?

Sign in
Research

Omega 3: Cardiovascular disease

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Nutraceutical: Omega 3

Indication: Cardiovascular disease

Source: Arch Intern Med, April 9, 2012; [Epub ahead of print]

Research: Although previous randomized, double-blind, placebo-controlled trials reported the efficacy of omega 3 fatty acid supplements in the secondary prevention of cardiovascular disease (CVD), the evidence remains inconclusive, according to researchers. Using a meta-analysis, they investigated the efficacy of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the secondary prevention of CVD. They searched PubMed, EMBASE and the Cochrane Library in April 2011. Then they independently reviewed and selected eligible randomized controlled trials. Of 1007 articles retrieved, 14 randomized, double-blind, placebo-controlled trials (involving 20,485 patients with a history of CVD) were included in the final analyses.
 
Results: Supplementation with omega 3 fatty acids did not reduce the risk of overall cardiovascular events, all-cause mortality, sudden cardiac death, myocardial infarction, congestive heart failure or transient ischemic attack and stroke. There was a small reduction in cardiovascular death, which disappeared when researchers excluded a study with major methodological problems. Researchers say the meta-analysis showed insufficient evidence of a secondary preventive effect of omega 3 fatty acid supplements against overall cardiovascular events among patients with a history of cardiovascular disease.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Topics